WHO alert, 23 December 2024
N°5/2024: Falsified IMFINZI (durvalumab) injection, lot BAVX; August 2025 update names India
Last checked 20 September 2026
On 23 December 2024 the WHO warned of falsified IMFINZI (durvalumab), a cancer immunotherapy, with lot number BAVX, which AstraZeneca confirmed it had not manufactured. The falsified vials were sold outside regulated supply chains. An update to the alert in August 2025 reported that the falsified lot had been identified in India, Pakistan and Uzbekistan. A further alert, N°3/2025, covered three more falsified lots. Patients receiving durvalumab should be treated only through licensed hospital pharmacies, and any vial with lot BAVX should be reported.
India link: The August 2025 update to the alert reported the falsified lot found in India, Pakistan and Uzbekistan
WHO Medical Product Alert N°5/2024: Falsified IMFINZI (durvalumab)
Scope. A record here does not by itself mean a product or company is unsafe or banned today. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Products named
- IMFINZI (durvalumab) 500 mg/10 ml injection, lot BAVX, falsified
- Genuine product: AstraZeneca
Official sources and primary records
- WHO
- WHO